Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have a Body Mass Index (BMI) ) ≥30 and ≤50 kilograms per square meter (kg/m²), or ≥27 kg/m² and \<30 kg/m², with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease~* Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires~Exclusion Criteria:~* Participants must not have type 1 or type 2 diabetes mellitus~* Participants must not have had an increase or decrease in body weight \> more than 5 kg (11 pounds) within the past 3 months~* Participants must not have had surgery for obesity or plan to have such surgery during the study~* Participants must not be using medications that promote weight loss or cause weight gain~* Participants must not drink excessive amounts of alcohol (more than 14 units a week for women or more than 21 units a week for men)~* Participants must not have used marijuana within the last 3 months.~* Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months~* Participants must not have active cancer within the last 5 years~* Participants must not have uncontrolled high blood pressure~* Participants must not have liver disease other than non-alcoholic fatty liver disease~* Participants must not have renal impairment with estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m2~* Participants must not have a history of acute or chronic pancreatitis symptomatic gallbladder disease or documented human immunodeficiency virus infection~* Participants must not have a major problem with depression or other mental illness within the last 2 years~* Participants must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)~* Female participants must not be pregnant, breast-feeding, or intend to become pregnant or of childbearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).
- 1 milligram (mg) LY3437943 (Type: EXPERIMENTAL): Participants received 1 mg LY3437943 administered as SC injection QW.
- 4 mg LY3437943 (2 mg) (Type: EXPERIMENTAL): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
- 4 mg LY3437943 (Type: EXPERIMENTAL): Participants received 4 mg LY3437943 administered as SC injection QW.
- 8 mg LY3437943 (2 mg) (Type: EXPERIMENTAL): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
- 8 mg LY3437943 (4 mg) (Type: EXPERIMENTAL): Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.
- 12 mg LY3437943 (2 mg) (Type: EXPERIMENTAL): Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.

Based on this trial design, predict the completion outcome and termination type (if applicable).